Press releases - Ypsomed

Changes in the Board of Directors at Ypsomed

05/18/2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) announces changes to the Board of Directors. The founder and Chairman of the Board of Directors of the Ypsomed Group Dr. h.c. Willy Michel will not stand for re-election as Chairman and member of the Board of Directors at the upcoming Annual General Meeting on 29 June 2022. The Board of Directors proposes to the Annual General Meeting 2022 to elect the current member of the Board of Directors, Gilbert Achermann as new Chairman. Simon Michel will be nominated for election as a new member of the Board of Directors.

Ypsomed, Abbott and CamDiab unveil new automated insulin delivery partnership for people with diabetes

04/27/2022 - 6:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed, Abbott and CamDiab will work to accelerate the development of an automated insulin delivery system for people living with diabetes. The system is being designed to include Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX algorithm, and Ypsomed’s mylife YpsoPump. The partnership demonstrates the companies’ collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes.

Topics:

Innovation & Digital Health

Ypsomed partners with CamDiab Ltd to drive on smartphone based adaptive automated insulin delivery (AID)

03/22/2022 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed partners with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach. During the first half of 2022, this easy-to-use loop solution will be launched for the mylife YpsoPump system, starting in selected major countries in Europe and followed by other territories in the course of the year. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX Android mobile application and are enabled to algorithm-based insulin delivery support including bolus from the personal smartphone.

Topics:

Innovation & Digital Health

Sébastien Delarive to become new Senior Vice President Diabetes Care.

Ypsomed focuses on growth and strengthens its business units

02/23/2022 - 7:00am Press Releases Ypsomed Group

Burgdorf – With the aim of focusing on changing customer needs, Ypsomed is stepwise optimizing the organisation of the business units and the Management Board.

Topics:

Access & Expansion

Ypsomed is growing and expects a further increase

11/04/2021 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SWX: YPSN) generated a growth in turnover of 11.6% in the first half of 2021/22 compared to the previous year and achieved a consolidated total turnover of CHF 222.6 million. On its continued growth trend, the company achieved an operating result (EBIT) of CHF 10.5 million. This corresponds to an increase of 23.1%. Net profit increased to CHF 7.1 million (previous year: CHF 6.7 million).